Department of Neuropsychiatry, Division of Child and Adolescent Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea.
Expert Rev Neurother. 2011 Nov;11(11):1541-52. doi: 10.1586/ern.11.151.
The most current treatment guidelines for schizophrenia recommend more than 1 year of maintenance therapy after the first psychotic episode, and more than 5 years of maintenance therapy after multiple psychotic episodes. Approximately two-thirds of such patients are known to relapse within 1 year and almost 90% of such patients may recur within 2 years. To maintain adequate consistent treatment, balancing the efficacy and safety/tolerability should be one of the most important clinical issues. In this respect, aripiprazole appears to be a good treatment option owing to its comparable efficacy, favorable safety and tolerability profile, including low incidence of parkinsonian symptoms, lack of prolactin elevation, decreased adrenergic and anticholinergic side effects, less weight gain and low incidence of metabolic syndrome. Hence this article aims to summarize the currently available clinical trial data of aripiprazole published from a number of large-scale randomized controlled studies, including a newer formulation of intramuscular injection as well as a once-monthly intramuscular depot formulation, to update knowledge of treatment options in patients with schizophrenia.
精神分裂症的最新治疗指南建议在首次精神病发作后进行超过 1 年的维持治疗，在多次精神病发作后进行超过 5 年的维持治疗。大约三分之二的此类患者在 1 年内会复发，几乎 90%的此类患者可能在 2 年内复发。为了维持足够的持续治疗，平衡疗效和安全性/耐受性应该是最重要的临床问题之一。在这方面，阿立哌唑似乎是一种很好的治疗选择，因为它具有相当的疗效，良好的安全性和耐受性，包括帕金森症状发生率低、催乳素升高不明显、肾上腺素能和抗胆碱能副作用减少、体重增加少、代谢综合征发生率低。因此，本文旨在总结阿立哌唑目前已发表的一些大型随机对照研究的临床试验数据，包括新的肌肉注射制剂和每月一次的肌肉注射长效制剂，以更新精神分裂症患者的治疗选择知识。
